Lansforsakringar Fondforvaltning AB publ Has $88.70 Million Stock Position in Pfizer Inc. $PFE

Lansforsakringar Fondforvaltning AB publ raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.4% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,158,825 shares of the biopharmaceutical company’s stock after acquiring an additional 103,600 shares during the quarter. Lansforsakringar Fondforvaltning AB publ’s holdings in Pfizer were worth $88,699,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Next Level Private LLC grew its position in Pfizer by 40.1% in the first quarter. Next Level Private LLC now owns 87,167 shares of the biopharmaceutical company’s stock valued at $2,448,000 after purchasing an additional 24,966 shares in the last quarter. North Star Investment Management Corp. boosted its stake in shares of Pfizer by 12.2% during the 1st quarter. North Star Investment Management Corp. now owns 181,035 shares of the biopharmaceutical company’s stock worth $5,083,000 after buying an additional 19,625 shares during the last quarter. 3Chopt Investment Partners LLC grew its holdings in shares of Pfizer by 19.5% in the 1st quarter. 3Chopt Investment Partners LLC now owns 10,467 shares of the biopharmaceutical company’s stock valued at $294,000 after acquiring an additional 1,706 shares in the last quarter. Three Magnolias Financial Advisors LLC increased its position in shares of Pfizer by 4.5% in the first quarter. Three Magnolias Financial Advisors LLC now owns 16,416 shares of the biopharmaceutical company’s stock valued at $464,000 after acquiring an additional 707 shares during the last quarter. Finally, Continuum Advisory LLC increased its position in shares of Pfizer by 14.0% in the first quarter. Continuum Advisory LLC now owns 32,250 shares of the biopharmaceutical company’s stock valued at $906,000 after acquiring an additional 3,964 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.4%

Shares of NYSE:PFE opened at $24.39 on Tuesday. Pfizer Inc. has a 52-week low of $23.11 and a 52-week high of $28.75. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market capitalization of $139.04 billion, a P/E ratio of 18.62 and a beta of 0.34. The company has a 50-day simple moving average of $25.88 and a 200 day simple moving average of $26.28.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the previous year, the business earned $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is 131.30%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer and Innovent’s GLP-1 drugs reportedly cleared a preliminary China insurance review, which could improve the commercial outlook for Ecnoglutide if it is eventually added to the country’s basic medical insurance catalogue. Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review
• Positive Sentiment: Investor commentary continues to frame Pfizer as a value and dividend stock, with bullish arguments pointing to its lower forward valuation and income appeal, which may be helping sentiment around the shares. Is Pfizer Inc. (PFE) A Good Stock To Buy Now?
• Positive Sentiment: Pfizer is also being highlighted as one of several reliable dividend names in a volatile market, reinforcing the stock’s defensive-income profile for investors. 3 No-Brainer Dividend Stocks to Buy Right Now
• Neutral Sentiment: Pfizer signed a SuperHuman platform license agreement with Distributed Bio, which is a strategic R&D move but not yet a clear near-term earnings driver. Wired News – Pfizer Signs SuperHuman Platform License Agreement with Distributed Bio
• Negative Sentiment: Recent coverage also continues to weigh on sentiment, noting a CFO departure and a late-stage clinical miss in Pfizer’s oncology pipeline, which reinforces concerns about execution and growth prospects. Read More.

Analyst Ratings Changes

Several research analysts recently commented on PFE shares. Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a report on Tuesday, June 23rd. Argus raised shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research note on Monday, March 2nd. Finally, Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, June 21st. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $28.82.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.